Michael L. Levitz

Michael L. Levitz is a declared insider at 3 companies (finance chief); the most frequent names are Analogic Corp, Anika Therapeutics, Inc. and Insulet Corp. We count 101 filings; the first trade dates from 17 July 2009 and the latest from 11 March 2024.

Both buying and selling appear: 3 purchases worth €214k, against 41 sales worth €3.0M. On balance, insiders were net sellers of €2.8M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 35 share grants and 22 option exercises.

In size, the median ticket on the buying side is €89k. Of 3 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. After 3 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -8.5%. Past outcomes like these are no guarantee of what comes next.

The newest entry dates from 12 March 2024: an option exercise, in Anika Therapeutics, Inc. The latest purchase dates back some time: it was published 1,701 days ago, on 14 March 2022. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.